Head & Neck Cancers | Specialty

Patient Selection for Systemic Therapy in DTC

July 9th 2014

Sequencing Therapies in Differentiated Thyroid Cancer

July 9th 2014

Available Treatment Options for RAI-Refractory DTC

July 9th 2014

Determining Treatment for RAI-Refractory Thyroid Cancer

July 9th 2014

Introduction: Radioactive Iodine-Refractory DTC

July 9th 2014

Dr. Ilson Discusses the Findings of the RTOG 0436 Trial

July 8th 2014

David H. Ilson, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the conclusions of the RTOG 0436 trial, a phase III trial of cisplatin, paclitaxel, and radiation with or without cetuximab in the non-operative treatment of esophageal cancer.

Dacomitinib Shows Promise in Head and Neck Cancer

July 7th 2014

Dacomitinib holds promise for the treatment of metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN).

Docetaxel May Cause Intoxication, FDA Warns

June 20th 2014

The FDA has issued a drug safety communication regarding the risk of intoxication with the intravenous ethanol-containing chemotherapy docetaxel.

Dr. Schlumberger Draws Conclusions From the SELECT Trial in Thyroid Cancer

June 17th 2014

Martin Schlumberger, MD, Institut Gustave Roussy, Villejuif Cedex, professor of oncology, University Paris-Sud, France, discusses the takeaway points for a community oncologist from the SELECT trial.

FDA Approves Lymphoseek for Head and Neck Cancer

June 13th 2014

The FDA has approved the radioactive diagnostic imaging agent Lymphoseek (technetium 99m tilmanocept) Injection to guide sentinel lymph node biopsy in patients with cancer of the head and neck.

Lenvatinib Likely to Become Standard in Resistant Differentiated Thyroid Cancer

May 31st 2014

Lenvatinib, a novel multityrosine kinase inhibitor, is highly effective against differentiated thyroid cancer that has become resistant to standard RAI therapy.

Study Supports Dialing Back Radiation for Some Patients With HPV-Positive Oropharyngeal Cancer

May 31st 2014

Patients with less aggressive, HPV-positive oropharyngeal cancer can be effectively treated with a lower-dose radiation regimen depending upon their response to combination induction therapy.

Dr. Seetharamu on Immunotherapy Treatment for Head and Neck Cancers

May 27th 2014

Nagashree Seetharamu, MD, assistant professor, Medicine (Hematology and Medical Oncology), Perlmutter Cancer Center at NYU Langone, discusses the possibility of using immunotherapy agents to treat head and neck cancers.

Vokes Charts a New Course in Head and Neck Cancer Treatment

May 22nd 2014

Everett E. Vokes, MD, was recognized by the "Giants of Cancer Care" awards program for his groundbreaking research into head and neck cancers.

Doxepin Rinse Relieves Pain in Patients With Radiation-Related Oral Mucositis

May 21st 2014

Doxepin rinse may prove to be a viable option for the relief of pain associated with oral mucositis (OM) in patients with head and neck cancers, according to findings of a phase III trial.

Review Study Suggests an Overdiagnosis and Overtreatment in Thyroid Cancer

April 30th 2014

A review study of trends in patients diagnosed with thyroid cancer from 1975 to 2009 suggest the cancer has been overdiagnosed, and therefore overtreated, according to Louise Davies, MD, MS, and H. Gilbert Welch, MD, MPH.

Study Suggests IMRT Improves Survival in Head and Neck Cancer

February 25th 2014

Intensity-modulated radiation therapy (IMRT) improved survival and reduced toxicities compared with conventional radiation treatment in patients with head and neck cancer, according to a recent database analysis.

Lenvatinib Extends PFS in Differentiated Thyroid Cancer

February 3rd 2014

The phase III SELECT trial of the investigational agent lenvatinib (E7080) met its primary endpoint of progression-free survival (PFS) in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC), according to Eisai Inc., the company that is developing the agent.

Dr. Brose on the FACT2 Study and the Treatment of ATC

January 24th 2014

Marcia S. Brose, MD, PhD, from the University of Pennsylvania, discusses the treatment of anaplastic thyroid cancer (ATC) and the FACT2 study.

Specific Gene Alterations Explain Survival Disparities in HNSCC

December 20th 2013

Alterations in specific genes involved in the formation of tissues and organs during embryonic development could be responsible for survival disparities seen between African-American and non-Latino white men with head and neck cancer.